Clinical Trials Browser

Phase 3 × Everolimus × Breast × Clear all

NCT07062965 2026-04-16

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06382948 2026-04-03

ADELA

Phase 3 Recruiting

Advanced Breast Cancer

NCT07407517 2026-02-12

POLARIS

Phase 3 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01674140 2026-02-10

e3

Phase 3 Active not recruiting

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase 3 Active not recruiting

Breast Neoplasms

NCT07024173 2026-01-26

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT06680921 2025-09-22

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Phase 3 Recruiting

Breast Neoplasms

NCT01805271 2025-05-14

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

Phase 3 Active not recruiting

Primary Non-metastatic Breast Cancer

NCT05065411 2024-02-26

VERU-024

Phase 3 Terminated

Breast Neoplasms

NCT05954442 2024-01-16

BCTOP-T-M03

Phase 3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3 Unknown

HER2+ Breast Cancer

NCT02137837 2021-01-28

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Phase 3 Terminated

37 enrolled 16 charts

Breast Neoplasms

NCT02511639 2020-12-03

MAIN-A

Phase 3 Completed

Breast Cancer Metastatic

NCT03176238 2020-04-07

EVEREXES

Phase 3 Completed

235 enrolled 11 charts

Breast Neoplasms

NCT02376985 2019-10-21

Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT

Phase 3 Completed

Breast Neoplasms

NCT00876395 2018-12-19

BOLERO-1

Phase 3 Completed

719 enrolled 25 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00863655 2017-05-02

BOLERO-2

Phase 3 Completed

724 enrolled 20 charts

Breast Neoplasms

NCT01007942 2017-04-05

BOLERO-3

Phase 3 Completed

569 enrolled 16 charts

Breast Neoplasms

NCT01626222 2017-02-23

MACS2096

Phase 3 Completed

Breast Neoplasms

NCT02404051 2016-06-15

FEVEX

Phase 3 Unknown

Breast Neoplasms, Neoplasm Metastasis

NCT00567554 2016-02-10

GeparQuinto

Phase 3 Completed

Breast Neoplasms

NCT01773460 2016-02-10

Evelyn

Phase 3 Terminated

Breast Neoplasms